Viatris (LTS:0A5V) Current Accrued Expense : $2,163 Mil (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Viatris Current Accrued Expense?

Viatris's Current Accrued Expense for the quarter that ended in Mar. 2024 was $2,163 Mil.

Viatris's quarterly Current Accrued Expense increased from Sep. 2023 ($2,143 Mil) to Dec. 2023 ($2,188 Mil) but then declined from Dec. 2023 ($2,188 Mil) to Mar. 2024 ($2,163 Mil).

Viatris's annual Current Accrued Expense declined from Dec. 2021 ($3,140 Mil) to Dec. 2022 ($2,108 Mil) but then increased from Dec. 2022 ($2,108 Mil) to Dec. 2023 ($2,188 Mil).

Viatris Current Accrued Expense Historical Data

The historical data trend for Viatris's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viatris Current Accrued Expense Chart

Viatris Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Current Accrued Expense

Get a 7-Day Free Trial

1,460.90

2,643.00

3,139.70

2,108.30

2,188.00

Viatris Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Current Accrued Expense	Get a 7-Day Free Trial															2,046.60	1,915.70	2,142.90	2,188.00	2,163.20

Viatris Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Viatris Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Viatris's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Viatris (LTS:0A5V) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Viatris Inc (LTS:0A5V) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

VTRS:USA MYL:Mexico 1VTRS:Italy VIA:Germany MYL:Austria

Address

1000 Mylan Boulevard, Canonsburg, PA, USA, 15317

Website

https://www.viatris.com

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Viatris (LTS:0A5V) Headlines

No Headlines